Celldex Therapeutics: all 51 studies

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• A Study of CDX-622 in Participants With Mild to Moderate AsthmaRecruitingNCT07330778Phase 1
• A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)RecruitingNCT07266402Phase 3
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaEnrolling by invitationNCT07256392Phase 3
• A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT03254927Phase 2Results posted
• A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedNCT02302339Phase 2Results posted
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerCompletedNCT01997333Phase 2Results posted
• A Study of Barzolvolimab in Patients With Atopic DermatitisActive, not recruitingNCT06727552Phase 2
• A Phase I Study of CDX-622CompletedNCT06650761Phase 1
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingNCT06455202Phase 3
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingNCT06445023Phase 3
• A Study of Barzolvolimab in Patients With Prurigo NodularisActive, not recruitingNCT06366750Phase 2
• A Study of CDX-585 in Patients With Advanced MalignanciesCompletedNCT05788484Phase 1
• A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCompletedNCT05774184Phase 2
• A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCompletedNCT05405660Phase 2
• A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT05368285Phase 2
• A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCompletedNCT05031624Phase 1
• A Study of CDX-0159 in Patients With Prurigo NodularisCompletedNCT04944862Phase 1
• A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic UrticariaCompletedNCT04548869Phase 1
• A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT04538794Phase 1
• A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesCompletedNCT04440943Phase 1
• A Phase 1 Study of CDX-0159CompletedNCT04146129Phase 1
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
• Expanded Access (Compassionate Use) Treatment Protocol RindopepimutNo longer availableNCT03068650
• Individual Patient Expanded Access-Glembatumumab VedotinNo longer availableNCT03067935
• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaTerminatedNCT02837991Phase 1
• A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid TumorsCompletedNCT02642016Phase 1
• A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1
• A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer PatientsCompletedNCT02473731Phase 1
• Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379CompletedNCT02456701Phase 1
• A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02386111Phase 1
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCompletedNCT02335918Phase 1/2
• A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
• A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced TumorsCompletedNCT02014909Phase 1
• Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseTerminatedNCT01791686Phase 1
• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCompletedNCT01498328Phase 2
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaCompletedNCT01480479Phase 3
• A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy VolunteersCompletedNCT01465139Phase 1
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
• A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast CancerCompletedNCT01156753Phase 2
• A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)TerminatedNCT01094496Phase 2
• A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedNCT00948961Phase 1/2
• A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)CompletedNCT00709462Phase 1
• Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast CancerCompletedNCT00704158Phase 1/2
• Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian CancerCompletedNCT00648102Phase 1
• Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult SubjectsCompletedNCT00498654Phase 2
• Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma MultiformeCompletedNCT00458601Phase 2
• A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT00412828Phase 1/2
• A Phase II Controlled Trial of Velafermin for Prevention of Oral MucositisCompletedNCT00323518Phase 2
• Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow TransplantCompletedNCT00104065Phase 2
• Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass SurgeryCompletedNCT00082121Phase 2

← Celldex Therapeutics overview and focus areas